Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Go back to Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results| (NASDAQ: AKTS) | Delayed: 24.79 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.79 | 52 Week High | $5.77 | |||
| Open | $24.79 | 52 Week Low | $1.51 | |||
| Day High | $24.79 | P/E | N/A | |||
| Day Low | $24.79 | EPS | $0.00 | |||
| Volume | 15 | |||||
